|
|
|
|
Product Candidates OverviewPipelineOrphan Drug Designations

Pipeline

USA

Product Candidate   Indication   Development Stage
Ampligen®   ME/CFS   NDA Active. Company in discussions with FDA to formulate path forward for potential approval
     
Ampligen®   Vaccine Adjuvant   Phase I/II – Research Collaboration with the University of Alabama
     
Ampligen®   Ovarian, Colorectal, and Peritoneal Cancers   Phase I/II - Sponsored by University of Pittsburgh
     
Ampligen®   Colorectal, Melanoma Cancer   Pre-clinical research collaboration with Georgia Regents University
     
Ampligen®   Renal Cell Carcinoma, Melanoma Cancers   Phase I/II Research Collaboration with Hahnemann University
Site Map | Privacy | Terms Of Use Copyright   Hemispherx Biopharma, Inc. | All Rights Reserved.